NASDAQ:CNAT - Conatus Pharmaceuticals Stock Price, Price Target & More

Conatus Pharmaceuticals trades on the NASDAQ under the ticker symbol "CNAT."

Conatus Pharmaceuticals Inc (NASDAQ:CNAT) announced its quarterly earnings results on Wednesday, May, 2nd. The biotechnology company reported ($0.17) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.17). The biotechnology company had revenue of $9.74 million for the quarter, compared to the consensus estimate of $8.88 million. Conatus Pharmaceuticals had a negative net margin of 49.30% and a negative return on equity of 64.30%. View Conatus Pharmaceuticals' Earnings History.

Conatus Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, August, 1st 2018. View Earnings Estimates for Conatus Pharmaceuticals.

6 brokers have issued 1-year target prices for Conatus Pharmaceuticals' stock. Their predictions range from $4.30 to $20.00. On average, they expect Conatus Pharmaceuticals' stock price to reach $12.1414 in the next year. View Analyst Ratings for Conatus Pharmaceuticals.

Conatus Pharmaceuticals saw a increase in short interest in April. As of April 30th, there was short interest totalling 2,596,203 shares, an increase of 55.3% from the April 13th total of 1,672,035 shares. Based on an average daily trading volume, of 647,431 shares, the days-to-cover ratio is presently 4.0 days. Approximately 10.5% of the shares of the stock are short sold.

Some companies that are related to Conatus Pharmaceuticals include Innate Pharma (IPHYF), Sinovac Biotech (SVA), Syros Pharmaceuticals (SYRS), ProMetic Life Sciences (PFSCF), Clearside Biomedical (CLSD), Merus (MRUS), American Brivision (Holding) (ABVC), Depomed (DEPO), Synergy Pharmaceuticals (SGYP), MediciNova (MNOV), Albireo (ALBO), Kala Pharmaceuticals (KALA), Tyme Technologies (TYME), Dermira (DERM) and Innovate (INNT).

Media coverage about CNAT stock has trended somewhat positive on Sunday, according to Accern Sentiment Analysis. Accern ranks the sentiment of news coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Conatus Pharmaceuticals earned a media sentiment score of 0.18 on Accern's scale. They also gave news articles about the biotechnology company an impact score of 46.13 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the near future.

Conatus Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional investors include MPM Asset Management LLC (8.20%), BlackRock Inc. (7.71%), Millennium Management LLC (1.19%), American Century Companies Inc. (0.36%), Alambic Investment Management L.P. (0.29%) and JPMorgan Chase & Co. (0.25%). View Institutional Ownership Trends for Conatus Pharmaceuticals.

CNAT stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC and Alambic Investment Management L.P.. View Insider Buying and Selling for Conatus Pharmaceuticals.

CNAT stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., MPM Asset Management LLC, American Century Companies Inc., JPMorgan Chase & Co., Wells Fargo & Company MN and The Manufacturers Life Insurance Company . View Insider Buying and Selling for Conatus Pharmaceuticals.

Shares of CNAT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of CNAT stock can currently be purchased for approximately $3.70.

Conatus Pharmaceuticals has a market capitalization of $111.23 million and generates $35.38 million in revenue each year. The biotechnology company earns $-17,390,000.00 in net income (profit) each year or ($0.61) on an earnings per share basis. Conatus Pharmaceuticals employs 35 workers across the globe.

Conatus Pharmaceuticals' mailing address is 16745 WEST BERNARDO DRIVE Suite 200, San Diego CA, 92127. The biotechnology company can be reached via phone at 858-376-2600 or via email at [email protected]